CD36 serves as a signaling receptor and free fatty acid (FFA) transporter in dyslipidemia: the role of dapagliflozin and alirocumab in downregulating atherogenic dyslipidemia via FFA uptake inhibition—experimental study
Receptor CD36 plays a critical role in LDF/atherogenic dyslipidemia, which were synergistically suppressed by combined dapagliflozin-alirocumab therapy.
Authors
- Jui‐Ning Yeh
- Hon‐Kan Yip (ORCID: https://orcid.org/0000-0002-6305-5717)
- Pei‐Lin Shao (ORCID: https://orcid.org/0000-0001-6920-0447)
- Xianwu Lan
- Jun Guo (ORCID: https://orcid.org/0000-0002-2089-7105)
- Chi‐Ruei Huang (ORCID: https://orcid.org/0000-0001-9646-8852)
- Yi‐Ting Wang (ORCID: https://orcid.org/0000-0003-2008-4435)
- Yi-Ling Chen
Institutions
- Chang Gung University of Science and Technology (TW)
- Asia University (TW)
- Chang Gung University (TW)
- China Medical University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- China Medical University Hospital (TW)
- First Affiliated Hospital of Jinan University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1097/js9.0000000000003451
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00